
The 2026 Fierce 50 includes people and organizations working on very different problems across biopharma and healthcare, from designing new proteins and developing cancer medicines to protecting vaccine science, improving health literacy and expanding representation in medicine. In this episode of “The Top Line,” Fierce Editor-in-Chief Ayla Ellison looks at the stories behind several of this year’s honorees, including Revolution Medicines’ work targeting RAS, the protein-design research of David Baker, Ph.D., and Michael Osterholm, Ph.D.’s, decision to put plans to step back from public health on hold. The episode also explores the work of Lisa Fitzpatrick, M.D., Hip Hop Public Health, Eric Topol, M.D., and Mary Owen, M.D., and the problems they have chosen to keep working on.See omnystudio.com/listener for privacy information.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

Inside the growing world of biopharma prediction markets

Clinical trials reach a new automation inflection point (Sponsored)

The future of RAS inhibitors

Why Diagnostic-Driven Therapies Still Miss Eligible Patients (Sponsored)
Free AI-powered recaps of The Top Line and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.